COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Entry into a Material Definitive Agreement

COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement

Story continues below

Exhibit No.

Description

4.1 Registration Rights Agreement, dated as of August21, 2017, by and between the Company and V-Sciences Investments Pte Ltd
10.1 Stock Purchase Agreement, dated as of August21, 2017, by and between the Company and V-Sciences Investments Pte Ltd
99.1 Press Release, dated August21, 2017


Coherus BioSciences, Inc. Exhibit
EX-4.1 2 d441726dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 COHERUS BIOSCIENCES,…
To view the full exhibit click here

About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

An ad to help with our costs